Method for activating helper T cell

Patent metadata

Field	Value
Publication number	US-9833493-B2
Application number	US-201314652298-A
Country	US
Kind code	B2
Filing date	Dec 16, 2013
Priority date	Dec 17, 2012
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to an MHC class II molecule selected from HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule.

First claim

The invention claimed is:

1. A method for activating helper T cells, comprising activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the helper T cells recognize a complex of the WT1 peptide and an MHC class II molecule selected from an HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule, wherein the WT1 peptide consists of:
(a) the amino acid sequence depicted in SEQ ID NO: 2; or
(b) an amino acid sequence in which one amino acid is substituted, deleted, or added in the amino acid sequence depicted in SEQ ID NO: 2; and
wherein the WT1 peptide is capable of binding to the MHC class II molecule.

2. A method for activating cytotoxic T cells, comprising administering a WT1 peptide, a polynucleotide encoding the WT1 peptide, an expression vector containing the polynucleotide, or cells containing the expression vector to a subject having an MHC class II molecule selected from an HLA-DRB1*08:02 molecule, an HLA-DRB113:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule, wherein the WT1 peptide consists of:
(a) the amino acid sequence depicted in SEQ ID NO: 2; or
(b) an amino acid sequence in which one amino acid is substituted, deleted, or added in the amino acid sequence depicted in SEQ ID NO: 2; and
wherein the WT1 peptide is capable of binding to the MHC class II molecule.

3. A method comprising administering a WT1 peptide, a polynucleotide encoding the WT1 peptide, an expression vector containing the polynucleotide, or cells containing the expression vector to a subject who has been diagnosed with cancer and has an MHC class II molecule selected from an HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule, wherein the WT1 peptide consists of:
(a) the amino acid sequence depicted in SEQ ID NO: 2; or
(b) an amino acid sequence in which one amino acid is substituted, deleted, or added in the amino acid sequence depicted in SEQ ID NO: 2; and
wherein the WT1 peptide is capable of binding to the MHC class II molecule.

4. The method according to claim 2 or claim 3 , comprising administering the WT1 peptide to the subject.

5. The method according to claim 4 , wherein the WT1 peptide consists of: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His (SEQ ID NO:2).

6. The method according to claim 1 , wherein the addition of the WT1 peptide to antigen presenting cells is carried out by contacting the antigen presenting cells with the WT1 peptide, or introducing a polynucleotide encoding the WT1 peptide or an expression vector containing the polynucleotide into the antigen presenting cells.

7. The method according to claim 1 , which comprises administering the WT1 peptide a subject having an MHC class II molecule selected from the group consisting of: an HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule.

8. The method according to claim 7 , wherein the WT1 peptide consists of: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His (SEQ ID NO:2).

9. The method according to claim 3 , wherein the MHC class II molecule is selected from an HLA-DRB1*08:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule.

Assignees

• Otsuka Pharma Co Ltd
• Int Inst Cancer Immunology Inc

Inventors

• Kubo Hiroshi
• Sogo Shinji
• Sugiyama Haruo

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• C07K14/70539

  MHC-molecules, e.g. HLA-molecules · CPC title